Clinical Trial

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Name: Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer — clinical trial record (NCT07139470)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is an open-label, single-arm, multicenter phase I/II study to evaluate the safety and efficacy of sac-TMT plus anlotinib in previously treated mTNBC. The study is expected to enroll up to 59 eligible patients.

Trial Details

NCT Number	NCT07139470
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital
Conditions	Triple Negative Breast Cancer
Enrollment	59 participants
Start Date	2025-08-15
Primary Completion	2027-04-15 (estimated)
Study Completion	2027-10-15 (estimated)
Updated on ClinicalTrials.gov	2025-08-24